In Nova Diagnostics, we offer a collection service for the Blood-based liquid biopsy, a minimally invasive test for cancer diagnosis that requires a simple blood draw for IMBDX.
It has recently risen as a possible substitute for tissue biopsy which includes a surgical procedure to obtain a piece of tumour tissue for analysis. Please visit their website www.imbdx.com to find out more or contact us for more information. The AlphaLiquid® series is a liquid biopsy platform that utilizes the most advanced tumour profiling technology along with Next Generation Sequencing, providing a comprehensive genomic solution for cancer patients.
AlphaLiquid® testing provides an in-depth analysis of cancer-related genetic mutations within approximately 2 weeks from receiving the collected blood specimen. The resulting report assists healthcare professionals in making improved clinical decisions for progressive cancer patients.
The test offers a non-invasive and safer approach compared to tissue biopsy, and thus can be repeated whenever necessary. It can be applied for anticancer drug selection, recurrence monitoring, as well as early cancer detection in the near future.
The KANEKA Direct RT-PCR kit SARS-CoV-2 is an in vitro diagnostic reagent that detects SARS-CoV-2 genes by real-time RT-PCR method, and simultaneously detects internal standard controls to prevent false negative judgment due to PCR inhibition. The detection device can use a general real-time PCR device and does not require a dedicated device. The operation time can be determined from the sample in about an hour, and it is possible to perform multiple tests per day. In conclusion, the product will contribute to increasing the number of PCR tests and will be useful in assisting the diagnosis of COVID-19 and preventing the spread of infection.